StocksMedium•10 November 2026•
1 min read
Palisade Bio Reports $113.6 Million Cash Balance and Advances Phase 2 Clinical Trials
Key Facts
1Palisade Bio reported $113.6 million in cash and cash equivalents as of September 30, 2026.
2The company dosed the first patient in the Phase 2b ASCENTRA-UC trial for PALI-2108 in ulcerative colitis.
3The company expects topline results from the ASCENTRA-UC trial in the fourth quarter of 2027.
Palisade Bio reported $113.6 million in cash and cash equivalents as of September 30, 2026. According to a statement released via GlobeNewswire, the company has dosed the first patient in its Phase 2b ASCENTRA-UC trial evaluating PALI-2108 for the treatment of ulcerative colitis. Management expects to report topline results from this clinical study in the fourth quarter of 2027.
PALI closed at $1.19 on November 9, 2026, after trading between a session low of $1.15 and a high of $1.23. These financial results coincide with the company's transition into mid-stage clinical development for its lead candidate, maintaining a stable cash position to support its ongoing research and development milestones.